Hemostemix Inc - Asset Resilience Ratio

Latest as of September 2025: 10.87%

Hemostemix Inc (HEM) has an Asset Resilience Ratio of 10.87% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Hemostemix Inc (HEM) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

CA$145.58K
≈ $105.31K USD Cash + Short-term Investments

Total Assets

CA$1.34 Million
≈ $968.53K USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2018)

This chart shows how Hemostemix Inc's Asset Resilience Ratio has changed over time. See free cash flow generation of Hemostemix Inc to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Hemostemix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Hemostemix Inc asset portfolio.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CA$0.00 0%
Short-term Investments CA$145.58K 10.87%
Total Liquid Assets CA$145.58K 10.87%

Asset Resilience Insights

  • Moderate Liquidity: Hemostemix Inc has 10.87% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Hemostemix Inc Industry Peers by Asset Resilience Ratio

Compare Hemostemix Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Protagenic Therapeutics
NASDAQ:PTIX
Biotechnology 0.00%
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Dianthus Therapeutics Inc.
NASDAQ:DNTH
Biotechnology 63.98%
TELIX Pharmaceuticals Ltd
AU:TLX
Biotechnology 32.29%
SOLENO THERAPEUT. DL-001
F:6XC
Biotechnology 41.74%
Shanghai Medicilon Inc
SHG:688202
Biotechnology 6.69%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Biotechnology 33.23%

Annual Asset Resilience Ratio for Hemostemix Inc (2017–2018)

The table below shows the annual Asset Resilience Ratio data for Hemostemix Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2018-12-31 0.00% CA$0.00
≈ $0.00
CA$1.66 Million
≈ $1.20 Million
--
2017-12-31 23.66% CA$1.25 Million
≈ $907.60K
CA$5.30 Million
≈ $3.84 Million
--
pp = percentage points

About Hemostemix Inc

V:HEM Canada Biotechnology
Market Cap
$8.18 Million
CA$11.31 Million CAD
Market Cap Rank
#27575 Global
#1169 in Canada
Share Price
CA$0.06
Change (1 day)
+0.00%
52-Week Range
CA$0.05 - CA$0.12
All Time High
CA$13.40
About

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopat… Read more